503 related articles for article (PubMed ID: 12096002)
1. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Houlihan HH; Rybak MJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Akins RL; Rybak MJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
[TBL] [Abstract][Full Text] [Related]
6. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
al-Nawas B; Shah PM
Infection; 1998; 26(3):165-7. PubMed ID: 9646108
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
Belley A; Neesham-Grenon E; McKay G; Arhin FF; Harris R; Beveridge T; Parr TR; Moeck G
Antimicrob Agents Chemother; 2009 Mar; 53(3):918-25. PubMed ID: 19104027
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
9. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
[TBL] [Abstract][Full Text] [Related]
10. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.
Mendes RE; Woosley LN; Farrell DJ; Sader HS; Jones RN
Antimicrob Agents Chemother; 2012 Mar; 56(3):1639-42. PubMed ID: 22183169
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin: mechanism of action.
Zhanel GG; Schweizer F; Karlowsky JA
Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
13. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Zelenitsky SA; Karlowsky JA; Zhanel GG; Hoban DJ; Nicas T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1407-8. PubMed ID: 9174212
[No Abstract] [Full Text] [Related]
14. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
15. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
17. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
18. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
19. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Arhin FF; Draghi DC; Pillar CM; Parr TR; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2009 Nov; 53(11):4762-71. PubMed ID: 19738026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
